Anthony S Wierzbicki

List of Publications by Year
in descending order

383	9,841	43973 48	56606 83
papers	citations	h-index	g-index

392	392	392	10497
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Agenda for Familial Hypercholesterolemia. Circulation, 2015, 132, 2167-2192.	1.6	539
2	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	0.8	316
3	Familial hypercholesterolaemia. Nature Reviews Disease Primers, 2017, 3, 17093.	18.1	315
4	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ, The, 2014, 349, g4356-g4356.	3.0	236
5	Homocysteine and cardiovascular disease: a review of the evidence. Diabetes and Vascular Disease Research, 2007, 4, 143-149.	0.9	235
6	The lipid and non-lipid effects of statins. , 2003, 99, 95-112.		217
7	Relation of erectile dysfunction to angiographic coronary artery disease. American Journal of Cardiology, 2003, 91, 230-231.	0.7	208
8	Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4Î± mutations in a large European collection. Diabetologia, 2005, 48, 878-885.	2.9	203
9	Familial hypercholesterolaemia: summary of NICE guidance. BMJ: British Medical Journal, 2008, 337, a1095-a1095.	2.4	203
10	“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Current Vascular Pharmacology, 2011, 9, 533-571.	0.8	187
11	Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Journal of Neurochemistry, 2002, 80, 727-735.	2.1	182
12	Multiple actions of high-density lipoprotein. Current Opinion in Cardiology, 2008, 23, 370-378.	0.8	180
13	Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. American Journal of Medical Genetics Part A, 2004, 128A, 285-293.	2.4	172
14	Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion, 2003, 19, 155-168.	0.9	156
15	Identification of PEX7 as the Second Gene Involved in Refsum Disease. American Journal of Human Genetics, 2003, 72, 471-477.	2.6	151
16	Relationship between Serum Copper, Ceruloplasmin, and Nonâ€“Ceruloplasmin-Bound Copper in Routine Clinical Practice. Clinical Chemistry, 2005, 51, 1558-1559.	1.5	111
17	“European Panel On Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Current Vascular Pharmacology, 2011, 9, 531-532.	0.8	110
18	Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) Genes: Association with Serum Sex Steroid Concentrations and Bone Mineral Density in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 344-351.	1.8	107

#	Article	IF	Citations
19	Î±â€Methylacylâ€CoA racemaseâ€ƒâ€“â€ƒan â€˜obscureâ€™ metabolic enzyme takes centre stage. FEBS Journal, 2008, 275, 1089-1102.	2.2	98
20	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	0.6	98
21	Effect of atorvastatin on plasma fibrinogen. Lancet, The, 1998, 351, 569-570.	6.3	96
22	Preserved Endothelial Function in Patients With Severe Hypertriglyceridemia and Low Functional Lipoprotein Lipase Activity. Journal of the American College of Cardiology, 1997, 29, 964-968.	1.2	86
23	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2013, 168, 192-200.	1.4	81
24	Erectile dysfunction and statin treatment in high cardiovascular risk patients. International Journal of Clinical Practice, 2006, 60, 141-145.	0.8	80
25	Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporosis International, 2010, 21, 1853-1861.	1.3	76
26	The chemical biology of branched-chain lipid metabolism. Progress in Lipid Research, 2003, 42, 359-376.	5.3	71
27	The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 954-957.	0.9	71
28	The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism. Genome Research, 2012, 22, 1144-1153.	2.4	70
29	Epicardial fat and vascular risk. Current Opinion in Cardiology, 2013, 28, 458-463.	0.8	70
30	The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Current Medical Research and Opinion, 2005, 21, 959-969.	0.9	68
31	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 183-190.	1.5	65
32	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. Diabetes Care, 2004, 27, 2569-2569.	4.3	65
33	Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. Human Molecular Genetics, 2001, 10, 1971-1982.	1.4	64
34	Asymmetric Dimethylarginine and Reduced Nitric Oxide Bioavailability in Young Black African Men. Hypertension, 2007, 49, 873-877.	1.3	63
35	Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart, 2008, 94, 754-758.	1.2	63
36	Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Journal of Molecular Medicine, 2006, 84, 203-214.	1.7	61

#	Article	IF	Citations
37	Plasma Lipid Profiles of Women With Intrahepatic Cholestasis of Pregnancy. Obstetrics and Gynecology, 2006, 107, 106-114.	1.2	61
38	Peroxisomal disorders affecting phytanic acid Î±-oxidation: a review. Biochemical Society Transactions, 2007, 35, 881-886.	1.6	61
39	New lipid-lowering drugs: an update. International Journal of Clinical Practice, 2012, 66, 270-280.	0.8	61
40	Statins, Muscle Disease and Mitochondria. Journal of Clinical Medicine, 2017, 6, 75.	1.0	61
41	The Uptake of Lipoprotein-Borne Phylloquinone (Vitamin K1) by Osteoblasts and Osteoblast-Like Cells: Role of Heparan Sulfate Proteoglycans and Apolipoprotein E. Journal of Bone and Mineral Research, 2002, 17, 426-433.	3.1	60
42	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	0.8	60
43	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. Current Medical Research and Opinion, 2000, 16, 139-146.	0.9	57
44	FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice, 2006, 60, 442-449.	0.8	57
45	Hypertension in adults: summary of updated NICE guidance. BMJ: British Medical Journal, 2019, 367, l5310.	2.4	57
46	Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 387-394.	0.2	52
47	Lipoprotein a: where are we now?. Current Opinion in Cardiology, 2009, 24, 351-357.	0.8	52
48	Utilization of Sterol Carrier Protein-2 by Phytanoyl-CoA 2-Hydroxylase in the Peroxisomal Î± Oxidation of Phytanic Acid. Chemistry and Biology, 2002, 9, 597-605.	6.2	51
49	Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes/Metabolism Research and Reviews, 2007, 23, 392-399.	1.7	50
50	Nonalcoholic fatty liver disease and lipids. Current Opinion in Lipidology, 2012, 23, 345-352.	1.2	49
51	Effects of Growth Hormone (GH) Replacement Therapy on Very Low Density Lipoprotein Apolipoprotein B100 Kinetics in Patients with Adult GH Deficiency: A Stable Isotope Study1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 307-316.	1.8	48
52	Should we expand the concept of coronary heart disease equivalents?. Current Opinion in Cardiology, 2014, 29, 389-395.	0.8	47
53	Doseâ€“response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. International Journal of Cardiology, 2002, 84, 53-57.	0.8	46
54	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. International Journal of Clinical Practice, 2010, 64, 1252-1259.	0.8	45

#	Article	IF	Citations
55	Daily and intermittent rosuvastatin 5â€‰mg therapy in statin intolerant patients: an observational study. Current Medical Research and Opinion, 2012, 28, 371-378.	0.9	45
56	Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 2623-2636.	2.0	45
57	Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Current Medical Research and Opinion, 2004, 20, 55-62.	0.9	44
58	Future Challenges for Microsomal Transport Protein Inhibitors. Current Vascular Pharmacology, 2009, 7, 277-286.	0.8	43
59	Erectile dysfunction: cardiovascular risk and the role of the cardiologist. International Journal of Clinical Practice, 2003, 57, 96-9.	0.8	43
60	A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. Journal of Human Hypertension, 2000, 14, 99-104.	1.0	42
61	Beyond LDL-C â€“ The Importance of Raising HDL-C. Current Medical Research and Opinion, 2002, 18, 36-44.	0.9	42
62	Identification of genetic heterogeneity in Refsum's disease. European Journal of Human Genetics, 2000, 8, 649-651.	1.4	41
63	Lipid lowering: another method of reducing blood pressure?. Journal of Human Hypertension, 2002, 16, 753-760.	1.0	41
64	Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Current Medical Research and Opinion, 2005, 21, 333-338.	0.9	40
65	Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone, 2011, 48, 1127-1132.	1.4	40
66	Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opinion on Biological Therapy, 2013, 13, 7-10.	1.4	39
67	Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart, 2013, 99, 175-180.	1.2	39
68	The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion, 2002, 18, 215-219.	0.9	38
69	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus, 2000, 9, 194-201.	0.8	37
70	A review of the lipid-related effects of fluvastatin. Current Medical Research and Opinion, 2005, 21, 231-243.	0.9	37
71	Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. Journal of Lipid Research, 2003, 44, 1481-1488.	2.0	36
72	HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Current Medical Research and Opinion, 2008, 24, 609-624.	0.9	36

#	Article	IF	Citations
73	Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs, 2012, 21, 667-676.	1.9	36
74	Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International Journal of Clinical Practice, 2006, 60, 1697-1706.	0.8	35
75	Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?. Current Vascular Pharmacology, 2008, 6, 13-22.	0.8	35
76	Adult Refsum Disease: A Form of Tapetoretinal Dystrophy Accessible to Therapy. Survey of Ophthalmology, 2010, 55, 531-538.	1.7	35
77	Erectile dysfunction and coronary heart disease. Current Opinion in Cardiology, 2015, 30, 416-421.	0.8	35
78	Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. Journal of Trace Elements in Medicine and Biology, 2008, 22, 50-53.	1.5	34
79	Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology, 2010, 21, 352-358.	1.2	34
80	Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 589-598.	1.3	34
81	Accuracy of Cardiovascular Risk Estimation for Primary Prevention in Patients Without Diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 183-190.	3.1	33
82	Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis, 2006, 185, 421-425.	0.4	33
83	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. International Journal of Clinical Practice, 2017, 71, e13032.	0.8	33
84	Cardiovascular Risk Factors Determine Erectile and Arterial Function Response to Sildenafil. American Journal of Hypertension, 2006, 19, 915-919.	1.0	32
85	Triglycerides. Current Opinion in Cardiology, 2012, 27, 398-404.	0.8	32
86	Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. International Journal of Clinical Practice, 1999, 53, 609-11.	0.8	32
87	Renin-Angiotensin System Polymorphisms and Coronary Events in Familial Hypercholesterolemia. Hypertension, 2000, 36, 808-812.	1.3	31
88	Cardiovascular risk factors and endothelial dysfunction. Clinical Science, 2004, 107, 609-615.	1.8	31
89	Factors regulating circulating vascular endothelial growth factor (VEGF): Association with bone mineral density (BMD) in post-menopausal osteoporosis. Cytokine, 2009, 46, 376-381.	1.4	31
90	Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology, 2009, 24, 372-379.	0.8	31

#	Article	IF	Citations
91	Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. American Journal of Cardiology, 2002, 89, 229-231.	0.7	30
92	Simple Sequence-specific-Primer-PCR Method To Identify the Three Main Apolipoprotein E Haplotypes. Clinical Chemistry, 2003, 49, 1945-1948.	1.5	30
93	Diagnosis and treatment of severe hypertriglyceridemia. Expert Review of Cardiovascular Therapy, 2012, 10, 505-514.	0.6	30
94	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. Atherosclerosis, 2018, 274, 16-22.	0.4	30
95	Surrogate markers, atherosclerosis and cardiovascular disease prevention. International Journal of Clinical Practice, 2008, 62, 981-987.	0.8	29
96	New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors. Current Pharmaceutical Design, 2011, 17, 943-949.	0.9	29
97	Copper:caeruloplasmin ratio. Journal of Clinical Pathology, 2006, 60, 441-442.	1.0	28
98	The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial. Clinical Therapeutics, 2012, 34, 67-76.	1.1	28
99	Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 401-411.	1.0	28
100	Radiotherapy, chemotherapy and atherosclerosis. Current Opinion in Cardiology, 2017, 32, 441-447.	0.8	28
101	â€˜Chemical co-substrate rescueâ€™ of phytanoyl-CoA 2-hydroxylase mutants causing Refsumâ€™s Disease. Chemical Communications, 2001, , 972-973.	2.2	27
102	Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice, 2011, 65, 379-385.	0.8	27
103	Screening for chronic comorbid diseases in people with <scp>HIV</scp>: the need for a strategic approach. HIV Medicine, 2013, 14, 1-11.	1.0	27
104	A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 63-71.	3.1	26
105	Smell testing: an additional tool for identification of adult Refsum's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1334-1336.	0.9	26
106	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clinical Transplantation, 2004, 18, 201-204.	0.8	26
107	High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. American Journal of Cardiology, 2000, 86, 547-549.	0.7	25
108	Getting better value from the NHS drug budget. BMJ: British Medical Journal, 2010, 341, c6449-c6449.	2.4	25

#	Article	IF	Citations
109	Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1801-1807.	1.8	24
110	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Current Medical Research and Opinion, 2004, 20, 811-818.	0.9	24
111	A Cross-Sectional Randomised Study of Fracture Risk in People with HIV Infection in the Probono 1 Study. PLoS ONE, 2013, 8, e78048.	1.1	24
112	Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 631-634.	0.2	23
113	Correspondence. Atherosclerosis, 2000, 148, 204.	0.4	23
114	Drug Treatment of Combined Hyperlipidemia. American Journal of Cardiovascular Drugs, 2001, 1, 327-336.	1.0	23
115	Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-Coenzyme A. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2545-2548.	1.0	23
116	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Current Medical Research and Opinion, 2005, 21, 299-305.	0.9	23
117	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Current Opinion in Cardiology, 2010, 25, 406-410.	0.8	23
118	CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. Journal of Lipid Research, 2013, 54, 3491-3505.	2.0	23
119	Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opinion on Biological Therapy, 2016, 16, 1125-1134.	1.4	23
120	Chronic heart failure in adults: summary of updated NICE guidance. BMJ: British Medical Journal, 2018, 362, k3646.	2.4	23
121	Lipid lowering therapy in patients with HIV infection. Lancet, The, 1998, 352, 1782.	6.3	22
122	Atorvastatin. Expert Opinion on Pharmacotherapy, 2001, 2, 819-830.	0.9	22
123	Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. Current Medical Research and Opinion, 2003, 19, 719-723.	0.9	22
124	Lipid-altering agents: the future. International Journal of Clinical Practice, 2004, 58, 1063-1072.	0.8	22
125	The ezetimibe Jonah: the trials and tribulations of an unlucky drug. International Journal of Clinical Practice, 2011, 65, 1207-1208.	0.8	22
126	Statins and noncardiac vascular disease. Current Opinion in Cardiology, 2012, 27, 392-397.	0.8	22

#	Article	IF	Citations
127	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. International Journal of Clinical Practice, 2012, 66, 622-630.	0.8	22
128	New therapies to reduce low-density lipoprotein cholesterol. Current Opinion in Cardiology, 2013, 28, 452-457.	0.8	22
129	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. Clinical Chemistry, 2016, 62, 428-435.	1.5	22
130	Adjusting copper concentrations for caeruloplasmin levels in routine clinical practice. Journal of Clinical Pathology, 2006, 59, 867-869.	1.0	21
131	Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. Journal of Nephrology, 2003, 16, 540-5.	0.9	20
132	High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 291-294.	0.2	19
133	Effect of moxonidine on lipid subfractions in patients with hypertension. International Journal of Clinical Practice, 2004, 58, 465-468.	0.8	19
134	Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart, 2005, 91, 1003-1007.	1.2	19
135	Dyslipidaemia and cardiovascular risk in HIV infection. Current Medical Research and Opinion, 2005, 21, 1717-1725.	0.9	19
136	Vitamin K and other markers of micronutrient status in morbidly obese patients before bariatric surgery. International Journal of Clinical Practice, 2015, 69, 638-642.	0.8	19
137	Triglycerides and cardiovascular disease. Current Opinion in Cardiology, 2021, 36, 469-477.	0.8	19
138	Hyperlipidaemia in Paediatric Patients. Drug Safety, 2010, 33, 115-125.	1.4	18
139	The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Current Medical Research and Opinion, 2011, 27, 63-69.	0.9	18
140	Pulmonary arterial hypertension and statins: an update. Current Opinion in Cardiology, 2011, 26, 322-326.	0.8	18
141	Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. European Journal of Preventive Cardiology, 2012, 19, 474-483.	0.8	18
142	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 537-547.	1.7	18
143	Transport of phytanic acid on lipoproteins in Refsum disease. Journal of Inherited Metabolic Disease, 1999, 22, 29-36.	1.7	17
144	Muddy waters: more stormy SEAS for ezetimibe. International Journal of Clinical Practice, 2008, 62, 1470-1473.	0.8	16

#	Article	IF	Citations
145	The relationship between gonadotrophins, gonadal hormones and bone mass in men. Clinical Endocrinology, 2008, 68, 94-101.	1.2	16
146	Aortic stenosis and lipids: does intervention work?. Current Opinion in Cardiology, 2010, 25, 379-384.	0.8	16
147	Vascular and Blood Pressure Effects of Folic Acid in Older Patients with Cardiovascular Disease. Journal of the American Geriatrics Society, 2001, 49, 1003-1004.	1.3	15
148	A fishy business: omega-3 fatty acids and cardiovascular disease. International Journal of Clinical Practice, 2008, 62, 1142-1146.	0.8	15
149	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology, 2008, 3, 237-255.	0.5	15
150	Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’. Current Pharmaceutical Design, 2010, 16, 3830-3838.	0.9	15
151	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. Vascular Health and Risk Management, 2021, Volume 17, 527-542.	1.0	15
152	Immunocytological diagnosis of primary cerebral non-Hodgkin's lymphoma.. Journal of Clinical Pathology, 1991, 44, 251-253.	1.0	14
153	Percentage non-caeruloplasmin bound copper. Clinical Biochemistry, 2007, 40, 749-750.	0.8	14
154	The copper/caeruloplasmin ratio in routine clinical practice in different laboratories. Journal of Clinical Pathology, 2009, 62, 60-63.	1.0	14
155	Limitations of non-ceruloplasmin-bound copper in routine clinical practice. Gut, 2007, 56, 154.	6.1	14
156	The role of lipid lowering in transplantation. International Journal of Clinical Practice, 1999, 53, 54-9.	0.8	14
157	Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. American Journal of Cardiology, 2001, 87, 338-340.	0.7	13
158	The effect of fibrateâ€“statin combination therapy on cardiovascular events: a retrospective cohort analysis. Current Medical Research and Opinion, 2010, 26, 2141-2146.	0.9	13
159	The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future. Clinical Pharmacology and Therapeutics, 2014, 96, 64-73.	2.3	13
160	Bile acid metabolism is altered in those with insulin resistance after gestational diabetes mellitus. Clinical Biochemistry, 2019, 64, 12-17.	0.8	13
161	Identification of PEX7 as the Second Gene Involved in Refsum Disease. Advances in Experimental Medicine and Biology, 2003, 544, 69-70.	0.8	13
162	Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clinical Endocrinology, 2001, 55, 777-787.	1.2	12

#	Article	IF	Citations
163	Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E1154-E1162.	1.8	12
164	New lipid-lowering agents. Expert Opinion on Emerging Drugs, 2003, 8, 365-376.	1.0	12
165	Ezetimibe-induced hyperlipidaemia. International Journal of Clinical Practice, 2005, 59, 3-5.	0.8	12
166	Low HDL-cholesterol: common and under-treated, but which drug to use?. International Journal of Clinical Practice, 2006, 60, 1149-1153.	0.8	12
167	Ideal lipid profile and genes for an extended life span. Current Opinion in Cardiology, 2011, 26, 348-355.	0.8	12
168	Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. International Journal of Clinical Practice, 2011, 65, 713-715.	0.8	12
169	The impact of lipoprotein lipase deficiency on health-related quality of life: a detailed, structured, qualitative study. Orphanet Journal of Rare Diseases, 2017, 12, 156.	1.2	12
170	Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model. Journal of Human Hypertension, 2021, 35, 455-461.	1.0	12
171	Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk. Hypertension, 2021, 77, 682-691.	1.3	12
172	Cholestatic liver dysfunction. Lancet, The, 1999, 354, 954.	6.3	11
173	Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size*. International Journal of Clinical Practice, 2007, 61, 1780-1782.	0.8	11
174	Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. International Journal of Clinical Practice, 2011, 65, 134-147.	0.8	11
175	Fibrates and niacin: is there a place for them in clinical practice?. Expert Opinion on Pharmacotherapy, 2014, 15, 2673-2680.	0.9	11
176	Identification of rare diseases by screening a population selected on the basis of routine pathology resultsâ€"the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. Journal of Clinical Pathology, 2018, 71, 608-613.	1.0	11
177	Effect of haemolysate preparation on measurement of red cell folate by a radioisotopic method.. Journal of Clinical Pathology, 1990, 43, 160-162.	1.0	10
178	Familial hyperchylomicronaemia. Lancet, The, 1996, 348, 1524.	6.3	10
179	The apolipoprotein E2 allele modulates activity and maximal velocity of the sodiumâ€"lithium countertransporter1. American Journal of Hypertension, 2002, 15, 633-637.	1.0	10
180	More on PROSPER. Lancet, The, 2003, 361, 1135-1136.	6.3	10

#	Article	IF	Citations
181	Lipemia Retinalis. New England Journal of Medicine, 2005, 353, 823-823.	13.9	10
182	Fibrates after the FIELD study: some answers, more questions. Diabetes and Vascular Disease Research, 2006, 3, 166-171.	0.9	10
183	Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. European Journal of Endocrinology, 2006, 154, 459-466.	1.9	10
184	Shape of the Nations survey and attitudes to cardiometabolic risk. Current Medical Research and Opinion, 2007, 23, 25-28.	0.9	10
185	Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. International Journal of Clinical Practice, 2015, 69, 738-742.	0.8	10
186	Impact of Therapeutic Inertia on Long-Term Blood Pressure Control. Hypertension, 2021, 77, 1350-1359.	1.3	10
187	Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C.. Journal of Medical Genetics, 1989, 26, 631-636.	1.5	9
188	Patients with Recurrent Renal Stones Have a Physico-Chemically Altered Urinary Tamm-Horsfall Glycoprotein Profile. Annals of Clinical Biochemistry, 1996, 33, 540-544.	0.8	9
189	Thrombotic vascular events after change of statin. Lancet, The, 1999, 353, 845.	6.3	9
190	Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. International Journal of Cardiology, 2003, 91, 107-109.	0.8	9
191	Statins and hypertension. Journal of Human Hypertension, 2006, 20, 554-556.	1.0	9
192	The relationship between serum copper and ceruloplasmin in routine clinical practice. International Journal of Clinical Practice, 2008, 62, 485-487.	0.8	9
193	Enhanced LDL-C reduction: lower is better. Does it matter how?. International Journal of Clinical Practice, 2008, 62, 518-520.	0.8	9
194	New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease. Recent Patents on Cardiovascular Drug Discovery, 2008, 3, 84-91.	1.5	9
195	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports, 2013, 15, 391.	1.3	9
196	Synthetic Statins: More Data on Newer Lipid-lowering Agents. Current Medical Research and Opinion, 2001, 17, 74-77.	0.9	9
197	Association of angiotensin converting enzyme DD genotype with hypertension in diabetes. Journal of Human Hypertension, 1995, 9, 671-3.	1.0	9
198	HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Current Medical Research and Opinion, 2000, 16, 139-46.	0.9	9

#	Article	IF	Citations
199	Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. European Heart Journal, 2001, 22, 972.	1.0	8
200	Chemical pathology and the new contract for GPs. Journal of Clinical Pathology, 2004, 57, 1022-1024.	1.0	8
201	Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology, 2007, 30, 155-160.	0.9	8
202	Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. International Journal of Cardiology, 2008, 128, 77-82.	0.8	8
203	Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes, Obesity and Metabolism, 2009, 11, 261-270.	2.2	8
204	Drugs for hypercholesterolaemia â€“ from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clinical Medicine, 2016, 16, 353-357.	0.8	8
205	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232092456.	1.1	8
206	Total research productivity in a pathology discipline. Journal of Clinical Pathology, 2002, 55, 495-498.	1.0	8
207	Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations. Current Pharmaceutical Design, 2014, 20, 6270-6275.	0.9	8
208	Relation between sodiumâ€“lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. American Journal of Hypertension, 2001, 14, 32-37.	1.0	7
209	Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von) Tj ETQq1 1 0.784314 rgBT /Over	1.7	7
210	Atorvastatin for Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2001, 286, 532.	3.8	7
211	Lipoproteins: from A to B and maybe C-III. International Journal of Clinical Practice, 2008, 62, 674-676.	0.8	7
212	Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. Current Vascular Pharmacology, 2014, 12, 155-167.	0.8	7
213	Statin myopathy. Current Opinion in Cardiology, 2016, 31, 417-425.	0.8	7
214	Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. International Journal of Clinical Practice, 2016, 70, 229-235.	0.8	7
215	Genetic risk scores in lipid disorders. Current Opinion in Cardiology, 2019, 34, 406-412.	0.8	7
216	Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill?. Current Opinion in Cardiology, 2020, 35, 428-433.	0.8	7

#	Article	IF	Citations
217	Does activity in research correlate with visibility?. Journal of Clinical Pathology, 2004, 57, 426-427.	1.0	6
218	Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs, 2004, 13, 1405-1418.	1.9	6
219	Clinical significance of oxidation from phytol to phytanic acid in man. Molecular Genetics and Metabolism, 2004, 83, 347.	0.5	6
220	Intervening on HDL-C: Is it possible? Does it work?*. International Journal of Clinical Practice, 2007, 61, 1782-1786.	0.8	6
221	Targeted versus global approaches to the management of hypercholesterolaemia. Perspectives in Public Health, 2008, 128, 248-254.	0.5	6
222	Vascular risk screening: possible or too much, too soon?. International Journal of Clinical Practice, 2009, 63, 989-996.	0.8	6
223	The hinterland of familial hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 475-483.	1.2	6
224	The Challenges of a Successful Pregnancy in a Patient with Adult Refsumâ€™s Disease due to Phytanoyl-CoA Hydroxylase Deficiency. JIMD Reports, 2016, 33, 49-53.	0.7	6
225	Familial Hypercholesterolaemia in the Era of Genetic Testing. Current Cardiology Reports, 2016, 18, 42.	1.3	6
226	Potential Options to Treat Hypertriglyceridaemia. Current Drug Targets, 2009, 10, 356-362.	1.0	6
227	Cardiovascular prevention: Frontiers in lipid guidelines. Clinical Medicine, 2020, 20, 36-42.	0.8	6
228	The Hematological and Electrophysiological Effects of Cobalamin. Annals of the New York Academy of Sciences, 1992, 669, 345-348.	1.8	5
229	Copper-64 metabolism in two patients with non-Wilsonian movement disorders and copper deficiency. Journal of the Neurological Sciences, 1993, 119, 85-90.	0.3	5
230	Natural Statins and Stroke. Circulation, 2000, 101, E45.	1.6	5
231	Correspondence. Atherosclerosis, 2000, 149, 221-222.	0.4	5
232	Very low plasma copper levels do not automatically imply severe copper deficiency. Annals of Clinical Biochemistry, 2005, 42, 405-405.	0.8	5
233	Newer, lower, better? Lipid drugs and cardiovascular disease - the continuing story. International Journal of Clinical Practice, 2007, 61, 1064-1067.	0.8	5
234	SEARCHing for JUPITER: starry-eyed optimism is not warranted. International Journal of Clinical Practice, 2009, 63, 685-688.	0.8	5

#	Article	IF	Citations
235	Hot and bothered: C-reactive protein, inflammation and atherosclerosis. International Journal of Clinical Practice, 2009, 63, 1550-1553.	0.8	5
236	Dyslipidaemia: whatâ€™s around the corner?. Clinical Medicine, 2014, 14, s41-s44.	0.8	5
237	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. BMJ Open, 2015, 5, e008678.	0.8	5
238	An update on trials of novel lipid-lowering drugs. Current Opinion in Cardiology, 2018, 33, 416-422.	0.8	5
239	Managing cardiovascular disease risk in hypertension. Lancet, The, 2020, 395, 869-870.	6.3	5
240	Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. International Journal of Clinical Practice, 2001, 55, 673-5.	0.8	5
241	Sheffield risk and treatment table for primary prevention of coronary heart disease. Lancet, The, 1996, 348, 1039-1040.	6.3	4
242	Laboratory Investigations by DNA Amplification: From Research to Practice. Annals of Clinical Biochemistry, 1998, 35, 5-11.	0.8	4
243	Effects of statins. Lancet, The, 2000, 356, 1195.	6.3	4
244	Impaired renal function and atherosclerosis in a Pakistani cohort. Current Medical Research and Opinion, 2005, 21, 1201-1207.	0.9	4
245	Review: Clinical aspects of the management of HIV lipodystrophy. British Journal of Diabetes and Vascular Disease, 2008, 8, 113-119.	0.6	4
246	Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice, 2009, 63, 1268-1270.	0.8	4
247	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 423-433.	0.7	4
248	Practice makes perfect: reflections on a primary care treatment-to-target study. International Journal of Clinical Practice, 2010, 64, 1006-1008.	0.8	4
249	Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug, Healthcare and Patient Safety, 2010, 2, 61.	1.0	4
250	HDL: who needs it?. International Journal of Clinical Practice, 2011, 65, 1111-1113.	0.8	4
251	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 35, 537.	1.7	4
252	Demand management of weekend haematology and clinical biochemistry requests. International Journal of Clinical Practice, 2019, 73, e13297.	0.8	4

#	Article	IF	Citations
253	Identification of patients with Fabry disease using routine pathology results: PATHFINDER (eGFR) study. International Journal of Clinical Practice, 2021, 75, e13672.	0.8	4
254	Profound hyponatraemia following an idiosyncratic reaction to diuretics. International Journal of Clinical Practice, 1998, 52, 278-9.	0.8	4
255	Ezetimibe: a new addition to lipid-lowering therapy. International Journal of Clinical Practice, 2003, 57, 653-5.	0.8	4
256	Hyperlipidaemia in Association with Benign Paraproteinaemia. Annals of Clinical Biochemistry, 1997, 34, 697-699.	0.8	3
257	Attaining United States and European Guideline LDL-C Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study). Current Medical Research and Opinion, 2000, 16, 205-207.	0.9	3
258	Are drugs interchangeable?. Lancet, The, 2000, 355, 317.	6.3	3
259	Coronary heart disease in Indian Asians. Lancet, The, 2000, 355, 1727-1728.	6.3	3
260	Statins and fractures. Lancet, The, 2001, 357, 1887.	6.3	3
261	Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Lupus, 2001, 10, 233-236.	0.8	3
262	Imidazole derivatives as cholesterol-lowering agents. International Journal of Cardiology, 2003, 90, 145-146.	0.8	3
263	Accuracy of Cardiovascular Risk Estimation in Patients without Diabetes. Clinical Science, 2003, 104, 16P-16P.	0.0	3
264	Hypertriglyceridaemia and malignancy. International Journal of Clinical Practice, 2005, 59, 253-255.	0.8	3
265	Cardiovascular risk assessment. Lancet, The, 2005, 365, 1305-1306.	6.3	3
266	Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. International Journal of Clinical Practice, 2008, 62, 701-707.	0.8	3
267	The 2007 Heart-UK Survey of Lipid Clinics and Clinical Practice in the UK. Atherosclerosis, 2008, 199, 234.	0.4	3
268	Targeting triglycerides in secondary prevention: should we bother?. International Journal of Clinical Practice, 2009, 63, 15-18.	0.8	3
269	The Poly-pill: does it work and is chronic therapy acceptable?. International Journal of Clinical Practice, 2010, 64, 1171-1173.	0.8	3
270	A renaissance for cardio-metabolic surgery: better outcomes and lower costs?. International Journal of Clinical Practice, 2011, 65, 728-732.	0.8	3

#	Article	IF	Citations
271	NO Problem: Arterial and Venous Endothelial Function and Erectile Dysfunction. European Urology, 2011, 59, 956-958.	0.9	3
272	The fats of life in diabetes. British Journal of Diabetes and Vascular Disease, 2012, 12, 216-220.	0.6	3
273	All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice, 2013, 67, 595-598.	0.8	3
274	Failure to THRIVE: the end for niacin?. Nature Reviews Cardiology, 2013, 10, 246-247.	6.1	3
275	Statinâ€“fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. Current Medical Research and Opinion, 2014, 30, 57-58.	0.9	3
276	Bariatric surgery in obese older people. Cardiovascular Endocrinology, 2015, 4, 60-66.	0.8	3
277	Further options for treating lipids in people with diabetes: targeting <scp>LDL</scp>â€cholesterol and beyond. Diabetic Medicine, 2018, 35, 1173-1180.	1.2	3
278	Ten tips for promoting your research. Cardiovascular Endocrinology and Metabolism, 2020, 9, 30-35.	0.5	3
279	Investigating raised creatine kinase. BMJ, The, 2021, 373, n1486.	3.0	3
280	Hairy leukaemic cell influx into the cerebrospinal fluid secondary to encephalomyelitis. Postgraduate Medical Journal, 1993, 69, 651-653.	0.9	2
281	Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. European Journal of Clinical Investigation, 1998, 28, 334-338.	1.7	2
282	Statins and fibrinogen. Lancet, The, 1998, 351, 1431-1432.	6.3	2
283	Measurement of atherosclerosis progression. Lancet, The, 2001, 358, 329-330.	6.3	2
284	Erythrocyte sodium-lithium countertransport in African American women. Journal of Human Hypertension, 2001, 15, 505-506.	1.0	2
285	Time to look beyond just lowering the serum concentration of low density lipoprotein - high density lipoprotein levels are also important. Perspectives in Public Health, 2001, 121, 98-101.	0.5	2
286	Statin therapy in people with diabetes and high-risk patients. British Journal of Hospital Medicine, 2003, 64, 16-19.	0.3	2
287	Spinning stars: ASTEROID's impact on atherosclerosis. Lancet, The, 2006, 367, 1655-1656.	6.3	2
288	Diabetic dyslipidaemia: the triad. Country Review Ukraine, 2006, 8, F30-F33.	0.8	2

#	Article	IF	Citations
289	Lipid lowering, statins and cancer. International Journal of Clinical Practice, 2006, 60, 1022-1024.	0.8	2
290	Dr Brian Gibberd (1931â€“2006): a pioneering clinician in Refsum's disease. Biochemical Society Transactions, 2007, 35, 862-864.	1.6	2
291	Primary and secondary prevention in obesity. International Journal of Clinical Practice, 2007, 61, 1431-1434.	0.8	2
292	Epidemiological Studies Are Meaningless without Proof of Long-Term Data Stability. American Journal of Medicine, 2008, 121, e7.	0.6	2
293	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology and Metabolism, 2010, 5, 825-834.	1.2	2
294	Putting protection first: vascular risk assessment in atypical populations. International Journal of Clinical Practice, 2010, 64, 664-666.	0.8	2
295	Cardiovascular disease and the seeds of innovation: a call for papers. International Journal of Clinical Practice, 2011, 65, 107-108.	0.8	2
296	Investigating mixed hyperlipidaemia. BMJ: British Medical Journal, 2011, 343, d5146-d5146.	2.4	2
297	Lumping and splitting in cardiovascular risk. International Journal of Clinical Practice, 2012, 66, 522-524.	0.8	2
298	Improving the odds: ezetimibe and cardiovascular disease. International Journal of Clinical Practice, 2015, 69, 390-395.	0.8	2
299	Prioritizing health outcomes in a limited world. Current Opinion in Lipidology, 2015, 26, 188-194.	1.2	2
300	Sensible economies: Demand management in blood science laboratories. International Journal of Clinical Practice, 2017, 71, e12942.	0.8	2
301	Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning. Annals of Clinical Biochemistry, 2017, 54, 501-503.	0.8	2
302	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. International Journal of Clinical Practice, 2018, 72, e13242.	0.8	2
303	Identification of patients with PompÃ© disease using routine pathology results: PATHFINDER (creatine) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	2
304	Screening for patients with Gaucher's disease using routine pathology results: PATHFINDER (ferritin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	2
305	Screening for secondary causes of hyperlipidaemia in general practice. BMJ: British Medical Journal, 1994, 309, 1373-1375.	2.4	2
306	The UK needs an Institute of Medicine. BMJ: British Medical Journal, 2008, 337, a1623-a1623.	2.4	2

#	Article	IF	Citations
307	Hypertriglyceridaemia and NK cell lymphoma. International Journal of Clinical Practice, 2003, 57, 921-2.	0.8	2
308	The Tissue Distribution of ?2-? Subunit Genes of the Voltage-Gated Calcium Channel in Rodent Tissues and NG108-15 Cells. Annals of the New York Academy of Sciences, 1993, 681, 422-424.	1.8	1
309	Maternal serum free beta hCG screening: Results of studies including 480 cases of Down syndromeâ€"problems with this approach. Prenatal Diagnosis, 1994, 14, 1093-1093.	1.1	1
310	Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. Journal of Human Hypertension, 2000, 14, 561-565.	1.0	1
311	Ezetimibe. American Journal of Cardiovascular Drugs, 2003, 3, 77-78.	1.0	1
312	Screening for cardiovascular disease. European Heart Journal, 2004, 25, 996.	1.0	1
313	The casino of life. Journal of Clinical Pathology, 2004, 57, 243-244.	1.0	1
314	Cost utility of prenatal diagnosis. Lancet, The, 2004, 363, 1165.	6.3	1
315	The role of dyslipidaemia in coronary heart disease. British Journal of Diabetes and Vascular Disease, 2005, 5, S2-S6.	0.6	1
316	Letter Regarding Article by Gazzaruso et al, â€œRelationship Between Erectile Dysfunction and Silent Myocardial Ischemia in Apparently Uncomplicated Type 2 Diabetic Patientsâ€• Circulation, 2005, 111, e18-9; author reply e18-9.	1.6	1
317	Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology, 2006, 1, 463-476.	0.5	1
318	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Current Vascular Pharmacology, 2007, 5, 173-174.	0.8	1
319	Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol. Current Opinion in Lipidology, 2007, 18, 227-229.	1.2	1
320	Raising HDL-C: back to the future?. International Journal of Clinical Practice, 2007, 61, 1069-1071.	0.8	1
321	Targets - who needs them? Success with statin therapies. International Journal of Clinical Practice, 2007, 61, 1239-1242.	0.8	1
322	Detection of small dense LDL-cholesterol: is it necessary to determine particle size?. Future Lipidology, 2008, 3, 23-25.	0.5	1
323	The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic. International Urology and Nephrology, 2011, 43, 821-825.	0.6	1
324	Sugar, sugar. International Journal of Clinical Practice, 2013, 67, 294-296.	0.8	1

#	Article	IF	Citations
325	Homozygous familial hypercholesterolemia. Clinical Lipidology, 2013, 8, 407-409.	0.4	1
326	Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?. International Journal of Clinical Practice, 2014, 68, 144-151.	0.8	1
327	The challenges of proprotein convertase subtilisinâ€“kexin-9 inhibitors for lipid guidelines and models of care. Current Opinion in Lipidology, 2017, 28, 470-476.	1.2	1
328	Computational models and neural nets: Fantastic modelsâ€”Where to find them and how to identify them. International Journal of Clinical Practice, 2019, 73, e13391.	0.8	1
329	Primum non nocere: Demand management in pathology and preventing harm. International Journal of Clinical Practice, 2019, 73, e13311.	0.8	1
330	Noncoronary Artery Disease in Familial Hypercholesterolemia: Underdiagnosis of Peripheral Arterial Disease?. Angiology, 2019, 70, 893-895.	0.8	1
331	Phenomics, Not Genomics, for Cardiovascular Risk Assessment. Circulation, 2020, 142, 821-823.	1.6	1
332	Low cholesterol syndrome and drug development. Current Opinion in Cardiology, 2020, 35, 423-427.	0.8	1
333	Role of Phytanoyl-CoA 2-Hydroxylase in Phytanic Acid Metabolism. Advances in Experimental Medicine and Biology, 2004, 544, 303-304.	0.8	1
334	National service framework's financial implications are huge. BMJ: British Medical Journal, 2000, 321, 705-705.	2.4	1
335	Drug treatment of hypercholesterolaemia: Establish diagnosis before treatment. BMJ: British Medical Journal, 1994, 308, 56-56.	2.4	1
336	Health promotion in general practice. BMJ: British Medical Journal, 1995, 310, 532-533.	2.4	1
337	People at risk of coronary heart disease should not be denied treatment with effective drugs for purely financial reasons. BMJ: British Medical Journal, 1998, 317, 80-80.	2.4	1
338	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. Lancet, The, 1996, 347, 466-7; author reply 468-9.	6.3	1
339	Diagnosis and management of hyperlipidaemia. International Journal of Clinical Practice, 1997, 51, 378-83.	0.8	1
340	SCREENING FOR INHERITED METABOLIC DISEASES IN ADULTS WITH NEUROLOGICAL DISEASE. Lancet, The, 1988, 331, 1101.	6.3	0
341	Autoimmunity: a risk factor for allosensitization to blood products?. BMJ: British Medical Journal, 1989, 298, 963-963.	2.4	0
342	Autoimmunity: a risk factor for allosensitisation to blood products?. BMJ: British Medical Journal, 1989, 298, 95-96.	2.4	0

#	Article	IF	Citations
343	Cerebral neoplastic angioendotheleosis complicated by hypercalcaemia.. Postgraduate Medical Journal, 1991, 67, 571-573.	0.9	0
344	Tissue-Specific Expression of Putative Domains of the Mouse Neuronal Alpha-2 and Delta Genes of the Voltage-Gated Calcium Channel in Rodent Tissues. Annals of the New York Academy of Sciences, 1993, 707, 472-475.	1.8	0
345	Molecular Biology Techniques. Annals of Clinical Biochemistry, 1993, 30, 332-333.	0.8	0
346	Paget's disease of bone.. BMJ: British Medical Journal, 1993, 306, 333-333.	2.4	0
347	Ambiguities in angiotensin-converting enzyme allele genotyping; a comparison of three methods. Journal of Human Hypertension, 1997, 11, 467-467.	1.0	0
348	Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. Journal of Human Hypertension, 1999, 13, 871-873.	1.0	0
349	Differing Relationships of Methylene Tetrahydrofolate Reductase Genotypes with Cardiovascular Risk in Familial and Polygenic Hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 431-434.	3.1	0
350	Classification of acute MI. European Heart Journal, 2000, 21, 857-858.	1.0	0
351	Stroke in systemic lupus erythematosus. Expert Review of Neurotherapeutics, 2002, 2, 385-390.	1.4	0
352	Ezetimibe: profile report. Drugs and Therapy Perspectives, 2003, 19, 5-7.	0.3	0
353	Accuracy of Cardiovascular Risk Estimation. Clinical Chemistry, 2003, 49, 706-707.	1.5	0
354	Raising high-density lipoprotein. International Journal of Clinical Practice, 2004, 58, 817-819.	0.8	0
355	Genetics and molecular biology: Genetic epidemiology. Current Opinion in Lipidology, 2004, 15, 699-701.	1.2	0
356	Molecular mechanisms of atherosclerosis. International Journal of Clinical Practice, 2005, 59, 1120-1120.	0.8	0
357	How aggressively should cholesterol targets be pursued?. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 232-233.	0.2	0
358	Shielding the population from the metabolic syndrome? There is one born every minute. International Journal of Clinical Practice, 2008, 62, 1132-1134.	0.8	0
359	Lipid-Lowering in the Elderly Patient. , 0, , 101-110.		0
360	Truthiness and quality improvement. International Journal of Clinical Practice, 2009, 63, 839-840.	0.8	0

#	Article	IF	Citations
361	Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effects. International Journal of Clinical Practice, 2010, 64, 1324-1326.	0.8	0
362	Cardiovascular screening: which populations, what measures of risk?. International Journal of Clinical Practice, 2011, 65, 3-5.	0.8	0
363	Statin wars: efficacy vs. cost. International Journal of Clinical Practice, 2011, 65, 108-111.	0.8	0
364	Secondary tests for stratification of risk for atherosclerosis. Current Medical Research and Opinion, 2013, 29, 597-599.	0.9	0
365	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. International Journal of Clinical Practice, 2013, 67, 391-393.	0.8	0
366	Lower, faster, better: the delusions of surrogate markers in hypertension. International Journal of Clinical Practice, 2013, 67, 822-824.	0.8	0
367	Clinical management of familial hypercholesterolemia: new insights from international guidelines and recent studies. Neurology International, 2014, 4, .	0.2	0
368	Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain. International Journal of Clinical Practice, 2014, 68, 1473-1477.	0.8	0
369	Moving the goalposts - towards cardiovascular prevention. International Journal of Clinical Practice, 2016, 70, 429-431.	0.8	0
370	Mind the gap - surviving in the modern world. International Journal of Clinical Practice, 2016, 70, 517-519.	0.8	0
371	Suboptimal rise in awakening-induced cortisol is an accurate marker of cortisol insufficiency in patients with normal renal function (eGFR >60â€‰mL/min). Annals of Clinical Biochemistry, 2018, 55, 496-499.	0.8	0
372	Review of referral criteria to lipid clinics and outcomes of treatment in 4 UK centres. Atherosclerosis, 2018, 275, e239.	0.4	0
373	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: Lipid clinic experience in 2 contrasting UK centres. Atherosclerosis, 2018, 275, e100.	0.4	0
374	Treating lipids in secondary prevention in a developing country: Lies, damn lies and the internet. International Journal of Clinical Practice, 2019, 73, 1-3.	0.8	0
375	An audit of research productivity in clinical biochemistry revisited. JRSM Open, 2019, 10, 205427041984418.	0.2	0
376	SPRINT: Running into trouble?. International Journal of Clinical Practice, 2020, 74, e13468.	0.8	0
377	Cost effectiveness of statins. British Heart Journal, 2000, 83, 713a-713.	2.2	0
378	Methodological discrepancies are not important. BMJ: British Medical Journal, 1994, 309, 1511-1511.	2.4	0

#	Article	IF	Citations
379	Strategies for reducing coronary risk factors in primary care. BMJ: British Medical Journal, 1995, 311, 263-263.	2.4	0
380	Full treatment of the costs and benefits is needed. BMJ: British Medical Journal, 1996, 313, 1143-1143.	2.4	0
381	Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology, 2007, 30, 155.	0.9	0
382	National service framework's financial implications are huge. BMJ: British Medical Journal, 2000, 321, 705.	2.4	0
383	Use of coronary calcification scores to predict coronary heart disease. JAMA - Journal of the American Medical Association, 2004, 291, 1831; author reply 1832-3.	3.8	0